NVCN News and Press, Neovasc Inc. From 01/17/23

Neovasc’s Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market Shockwave Medical Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Full Year 2023 Revenue Guidance SANTA CLARA, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Sh...

VANCOUVER, BC, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entere...

VANCOUVER and MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIR...

Neovasc Inc. (NVCN) Q3 2022 Earnings Conference Call November 10, 2022 04:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President & Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participan...

Neovasc press release ( NASDAQ: NVCN ): Q3 GAAP EPS of -$3.00 misses by $0.18 . Revenue of $0.92M (+31.4% Y/Y) misses by $0.12M . For further details see: Neovasc GAAP EPS of -$3.00 misses by $0.18, revenue of $0.92M misses by $0.12M

VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights ...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Centers for Medicare and Medicaid Services ("CMS") has assigned the Neovasc Reducer™ ("Reduc...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Cole...

Neovasc ( NASDAQ: NVCN ) on Tuesday said it would put on hold further development of its Tiara device for the transcatheter treatment of mitral valve disease. The company will additionally put the European CE-Marking regulatory approval process on hold for the device. ...

New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - September 20, 2022 - Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX : NVCN ) announced positive clinica...